Sanofi and Regeneron have vowed to reduce the net price to US payers of Praluent, or alirocumab, after the drug, in combination with maximally tolerated statins, showed a significant decrease in cardiovascular events in high-risk patients during a clinical trial. "We hope that our unprecedented approach to collaborating with payers and other stakeholders demonstrates that it is possible to bring major innovation to patients at a price that aligns with the value delivered," said Regeneron President and Chief Executive Leonard Schleifer.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.